MADISON, Wis.--(BUSINESS WIRE)--Roche NimbleGen, Inc. has launched NimbleGen Comparative Genomic Hybridization (CGH) microarrays in a 12x135K format for analysis of DNA copy number variation. NimbleGen CGH 12x135K arrays allow simultaneous analysis of 12 independent sample pairs on a single microarray slide, each with 135,000 empirically tested long oligonucleotide probes. This new array format will enable rapid and cost-effective analysis of DNA copy number variation associated with human genetic disease, genomic disorders, cancer, and other complex diseases for research purposes.
Similar to the NimbleGen 2.1 million feature (2.1M) arrays, the 12x135K arrays are manufactured on Roche NimbleGen’s new HD2 platform, a next generation light-directed microarray synthesizer with increased system contrast providing improved sensitivity and reproducibility compared to the earlier 385K and 4x72K arrays. The launch of NimbleGen CGH 12x135K arrays is further supported with a new release of Roche NimbleGen’s NimbleScan v2.5 software that includes an Experimental Metrics Report and enhanced analysis features for NimbleGen CGH arrays.
A single catalog array design, Human CGH 12x135K Whole-Genome Tiling v2.0, is available and enables genome-wide detection of copy number gains and losses down to ~100kb in size. Similar to the NimbleGen human whole-genome designs currently available in 2.1M, 385K, and 4x72K array formats, the Human CGH 12x135K Whole-Genome Tiling v2.0 array has enhanced probe coverage of segmental duplication regions that are often associated with pathogenic chromosomal rearrangements.
For researchers interested in targeted analysis of chromosomal regions, genes, or copy number variants (CNVs), Roche NimbleGen offers rapid and cost-effective creation of custom arrays for any eukaryotic organism. Custom CGH array designs consisting of either uniform or mixed-density probe spacing can be created for all available array formats (12x135K, 2.1M, 385K, 4x72K) and may include whole genomes, single chromosomal regions, or multiple loci of interest.
The release of NimbleGen CGH 12x135K arrays follows the launch earlier this year of our CGH 2.1M feature arrays. NimbleGen CGH 2.1M arrays offer ultra-high resolution detection of CNVs, down to ~5kb resolution using a single Human CGH 2.1M Whole-Genome Tiling v2.0 array. Gerd Maass, CEO of Roche NimbleGen, stated: “The launch of NimbleGen CGH 2.1M and 12x135K arrays positions Roche NimbleGen as a leading provider of CGH microarrays and services offering both ultra-high resolution discovery and large-scale validation of CNVs on a single platform. These tools will facilitate the identification of genetic variants associated with a variety of rare and common diseases including diabetes, cancer, psychiatric disorders, and autoimmune disease.”
Roche NimbleGen is a leading innovator, manufacturer, and supplier of a proprietary suite of DNA microarrays, consumables, instruments, and services. Roche NimbleGen uniquely produces high-density arrays of long oligo nucleotide probes that provide greater information content and higher data quality necessary for studying the full diversity of genomic and epigenomic variation. The improved performance is made possible by Roche NimbleGen’s proprietary Maskless Array Synthesis (MAS) technology, which uses digital light processing and rapid, high-yield photochemistry to synthesize long oligonucleotide, high-density DNA microarrays with extreme flexibility. For more information about Roche NimbleGen, please visit the company’s website at www.nimblegen.com
Headquartered in Basel, Switzerland, Roche is one of the world’s leading research-focused healthcare groups in the fields of pharmaceuticals and diagnostics. As the world’s biggest biotech company and an innovator of products and services for the early detection, prevention, diagnosis and treatment of diseases, the Group contributes on a broad range of fronts to improving people’s health and quality of life. Roche is the world leader in in-vitro diagnostics and drugs for cancer and transplantation, and is a market leader in virology. It is also active in other major therapeutic areas such as autoimmune diseases, inflammatory and metabolic disorders and diseases of the central nervous system. In 2007 sales by the Pharmaceuticals Division totalled 36.8 billion Swiss francs, and the Diagnostics Division posted sales of 9.3 billion francs. Roche has R&D agreements and strategic alliances with numerous partners, including majority ownership interests in Genentech and Chugai, and invested over 8 billion Swiss francs in R&D in 2007. Worldwide, the Group employs about 80,000 people. Additional information is available on the Internet at www.roche.com.
NIMBLEGEN is a trademark of Roche.